

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Timothy E. BENSON et al.

Packet No.:

00481.CN1

12/21/01
PTOCRYSTALLIZATION AND STRUCTURE DETERMINATION OF GLYCOSYLATED
HUMAN BETA SECRETASE, AN ENZYME IMPLICATED IN ALZHEIMER'S DISEASE

Assistant Commissioner for Patents

ATTN: Box Patent Application

Washington, D.C. 20231

JC858 U.S. PTO
10/027277

12/21/01

We are transmitting the following documents along with this Transmittal Sheet (which is submitted in triplicate):

☒ Utility Patent Application: Specification (44 pgs); Claims (25 claims on 3 pgs); 1 pg Abstract.☒ Application Data Sheet: 3 pgs.☒ 6 Sheets of Formal drawings.☐ A signed Declaration and Power of Attorney (pgs).☒ A return postcard.☐ An Assignment of the invention to _____ and Recordation Form Cover Sheet (pgs total).☐ A check in the amount of \$40.00 to cover the Assignment Recording Fee.☒ Computer readable form of "Sequence Listing." Applicants state that the paper copy form (included herewith)(4 pgs.) of the "Sequence Listing" section of the present application, and the computer readable form submitted herewith, are the same.☒ Other: Request for Filing A Continuation Application Under Rule §1.53(b) (3pgs.); Communication (1 pg.); and Nonpublication Request Under 35 U.S.C 122(b)(2)(B)(i) - (1 pg); copy of previously filed Declaration and Power of Attorney (3 pgs.); Preliminary Amendment-including Appendix A (3pgs.).☒ A check in the amount of \$1,082.00 to cover the filing fee, which is calculated below:

APPLICATION FILING FEE

| | Number of Claims Filed (1) | Claims Included in Basic Filing Fee (2) | Number of Extra Claims (1-2) | Cost per Extra Claim | Fee Required |
|---|----------------------------------|---|------------------------------------|-------------------------|--------------|
| Total Claims | 25 | 20 = | 5 | x \$18 = | \$90.00 |
| Independent Claims | 6 | 3 = | 3 | x \$84 = | \$252.00 |
| One or More Multiple Dependent Claims Presented? If Yes, Enter \$280 Here → | | | | | |
| Enter Basic Filing Fee (Utility Patent-\$740) Here → | | | | | \$740.00 |
| Total Application Filing Fee | | | | | \$1,082.00 |

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 13-4895. Triplicate copies of this sheet are enclosed.

MUETING, RAASCH & GEBHARDT, P.A.

Customer Number: 26813

By: Loren D. Albin

Name: Loren D. Albin

Reg. No.: 37,763

Direct Dial: 612-305-1225

Facsimile: 612-305-1228

CERTIFICATE UNDER 37 CFR §1.10:

"Express Mail" mailing label number: EL 888273564 USDate of Deposit: December 21, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, ATTN: Box Patent Application, Washington, D.C. 20231.

By: Sam HERPrinted Name: SAM HER

(LARGE ENTITY TRANSMITTAL UNDER RULE 1.10)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Timothy E. BENSON et al.)
Serial No.: Unassigned)
Filed: Herewith)
Group Art Unit: Unknown
Examiner: Unassigned

For: CRYSTALLIZATION AND STRUCTURE DETERMINATION OF
GLYCOSYLATED HUMAN BETA SECRETASE, AN ENZYME
IMPLICATED IN ALZHEIMER'S DISEASE

COMMUNICATION

Assistant Commissioner for Patents
ATTN: Box Patent Application
Washington, D.C. 20231

Sir:

In accordance with Rule §1.821(e), the information recorded in computer
readable form is identical to the written Sequence Listing, both of which are submitted herewith.

CERTIFICATE UNDER 37 C.F.R. 1.10:

Express Mail number: EL888273564US
Date of Deposit: December 21, 2001


I hereby certify that this paper or fee is being
deposited with the United States Postal Service
"Express Mail Post Office to Addressee" service
under 37 CFR §1.10 on the date indicated above
and is addressed to the Assistant Commissioner
for Patents, **ATTN: Box Patent Application**,
Washington, D.C. 20231.


SAM H. H. H.

Respectfully submitted,
Timothy E. Benson et al.
By their Representatives,
Mueiting, Raasch & Gebhardt, P.A.
P.O. Box 581415
Minneapolis, MN 55458-1415
Phone: (612)305-1220
Facsimile: (612)305-1228
Customer Number 26813

December 21, 2001
Date

By:


Loren D. Albin
Reg. No. 37,763
Direct Dial (612)305-1225

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | | |
|---------------|----------------------------|----------|---------------------|----------|
| Docket Number | Anticipated Classification | | Prior Application | |
| 00481.CN1 | Class | Subclass | Examiner Unknown | Art Unit |

**REQUEST FOR FILING A CONTINUATION APPLICATION
UNDER RULE §1.53(b)**

Assistant Commissioner for Patents
Attn: Box PATENT APPLICATION
Washington, D.C. 20231

Sir:

This is a request for filing a continuation application under 37 CFR §1.53(b) of Serial No. 09/808,262, Confirmation No. 3365, filed on March 14, 2001, entitled CRYSTALLIZATION AND STRUCTURE DETERMINATION OF GLYCOSYLATED HUMAN BETA SECRETASE, AN ENZYME IMPLICATED IN ALZHEIMER'S DISEASE by the following inventor(s) (name, address, and citizenship):

Timothy E. BENSON
2690 Timberleaf Lane
Kalamazoo, MI 49006
Citizenship: USA

2. Jim D. DURBIN
4822 Idlewood Ave.
Portage, MI 49024
Citizenship: USA

3. D. Bryan PRINCE
412 North Riverview Dr.
Parchment, MI 49004
Citizenship: USA

- Enclosed is a copy of the specification (including claims, abstract, and drawings) as filed in the prior application.
2. X Enclosed is a new specification (including claims and abstract). The entire disclosure of the prior application is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference.
3. X Enclosed is a copy of the Declaration and Power of Attorney filed in the prior application.
4. — Enclosed is a newly executed Declaration and Power of Attorney.
5. X Enclosed are drawings (6 sheets).
6. — Cancel in this application claims — before calculating the filing fee. (At least one independent claim must be retained for filing purposes.)
7. X A preliminary amendment is enclosed.

Filed: December 21, 2001

Title: CRYSTALLIZATION AND STRUCTURE DETERMINATION OF GLYCOSYLATED HUMAN BETA SECRETASE, AN ENZYME IMPLICATED IN ALZHEIMER'S DISEASE

8. X The filing fee is calculated below:

| CLAIMS AS FILED | | | |
|------------------------------------|--------------|-------------|--------------------------|
| NUMBER FILED | NUMBER EXTRA | RATE | BASIC FEE \$740/\$370 |
| Total Claims 25-20 = | 5 | \$18/\$9 | \$90 |
| Independent Claims 6-3 = | 3 | \$84/\$42 | \$252 |
| MULTIPLE DEPENDENT CLAIM PRESENTED | | \$280/\$140 | |
| FILING FEE: | | | \$1,082 |

9. X A check in the amount of \$ 1,082 is attached.
10. X The Commissioner is hereby authorized to charge any additional fees as set forth in 37 CFR §1.16 to 1.18 which may be required by this paper or credit any overpayment to Account No. 13-4895.
11. — This application is being filed by less than all of the inventors named in the prior application. Please delete the names of the following inventor(s) who are not inventors of the invention claimed in the present application:
12. X Amend the specification by inserting as the first sentence on page 1, the following: -- This is a continuation of application Serial No. 09/808,262, filed March 14, 2001, (pending), which is a continuation-in-part of U.S. Application Serial No. 09/747,420, filed December 23, 2000, both of which are incorporated herein by reference.--
13. — Priority of foreign application Serial No. —, filed on — in (country) — is claimed under 35 U.S.C. §119.
14. X The prior application is assigned of record to Pharmacia & Upjohn Company.
15. X The Power of Attorney in the prior application is to:

Ann M. Mueting
 Mueting, Raasch & Gebhardt, P.A.
 P.O. Box 581415
 Minneapolis, MN 55458-1415
Customer Number 26813

Filed: December 21, 2001


Title: CRYSTALLIZATION AND STRUCTURE DETERMINATION OF GLYCOSYLATED HUMAN BETA SECRETASE, AN ENZYME IMPLICATED IN ALZHEIMER'S DISEASE

Address all future communications to:

MUETING, RAASCH & GEBHARDT, P.A.
P.O. Box 581415
Minneapolis, Minnesota 55458-1415
Customer Number 26813

Attn: Ann M. Mueeting
(Telephone: 612-305-1220)
(Facsimile: 612-305-1228)

Date: December 21, 2001


Loren D. Albin
Reg. No. 37,763
Direct Dial (612)305-1225

LDA/sh

"Express Mail" mailing label number EL888273564US

Date of Deposit December 21, 2001.

I hereby certify that this paper and/or fee is/are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Attn: Box PATENT APPLICATION, Washington, D. C. 20231.


Name: SAM HER

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**NONPUBLICATION REQUEST
UNDER
35 U.S.C. 122(b)(2)(B)(i)**

First Named Inventor

Timothy E. BENSON

Title

Crystallization and Structure Determination of Glycosylated Human Beta Secretase
Alzheimer's Disease

Atty Docket Number


00481.CN1

I hereby certify that the invention disclosed in the attached application **has not and will not be** the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing.

I hereby request that the attached application not be published under 35 U.S.C. 122(b).

December 21, 2001

Date



Signature

Loren D. Albin

Typed or printed name

This request must be signed in compliance with 37 CFR 1.33(b) and submitted with the application **upon filing**.

Applicant may rescind this nonpublication request at any time. If applicant rescinds a request that an application not be published under 35 U.S.C. 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant **must** notify the United States Patent and Trademark Office of such filing within forty-five (45) days after the date of the filing of such foreign or international application. **Failure to do so will result in abandonment of this application (35 U.S.C. 122(b)(2)(B)(iii)).**